Literature DB >> 12725871

Recent advances in alpha1-adrenoceptor pharmacology.

Taka-aki Koshimizu1, Akito Tanoue, Akira Hirasawa, Junji Yamauchi, Gozoh Tsujimoto.   

Abstract

alpha(1)-Adrenergic receptors (ARs) mediate some of the main actions of the natural catecholamines, adrenaline and noradrenaline. They participate in many essential physiological processes, such as sympathetic neurotransmission, modulation of hepatic metabolism, control of vascular tone, cardiac contraction, and the regulation of smooth muscle activity in the genitourinary system. Here, we review recent progress on subtype-specific subcellular localization, participation in signaling cascades, and the pivotal function of alpha(1)-ARs, as delineated through studies on genetically engineered animals. Together, these findings will provide new insights into the physiological and pathophysiological roles of the alpha(1)-ARs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12725871     DOI: 10.1016/s0163-7258(03)00033-0

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  14 in total

1.  Neurotrophins regulate Schwann cell migration by activating divergent signaling pathways dependent on Rho GTPases.

Authors:  Junji Yamauchi; Jonah R Chan; Eric M Shooter
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-25       Impact factor: 11.205

2.  alpha1-Adrenoceptors in proximal segments of tail arteries from control and reserpinised rats.

Authors:  Susana Y Kamikihara; André Mueller; Vanessa Lima; Juliana Akinaga; Fernanda D Nojimoto; Anthony Castilho; José Buratini; André S Pupo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-04       Impact factor: 3.000

Review 3.  The specificity and molecular basis of alpha1-adrenoceptor and CXCR chemokine receptor dimerization.

Authors:  Graeme Milligan; Shirley Wilson; Juan F López-Gimenez
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

Review 4.  Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine.

Authors:  Yoshiyuki Kojima; Shoichi Sasaki; Yutaro Hayashi; Gozoh Tsujimoto; Kenjiro Kohri
Journal:  Nat Clin Pract Urol       Date:  2009-01

5.  5-HT1A receptor pharmacophores to screen for off-target activity of α1-adrenoceptor antagonists.

Authors:  Tony Ngo; Timothy J Nicholas; Junli Chen; Angela M Finch; Renate Griffith
Journal:  J Comput Aided Mol Des       Date:  2013-04-27       Impact factor: 3.686

6.  Epigenetic regulation of human alpha1d-adrenergic receptor gene expression: a role for DNA methylation in Sp1-dependent regulation.

Authors:  Gregory A Michelotti; D Marshall Brinkley; Daniel P Morris; Michael P Smith; Raphael J Louie; Debra A Schwinn
Journal:  FASEB J       Date:  2007-03-23       Impact factor: 5.191

7.  Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the alpha1A-adrenoceptor.

Authors:  L Quinton; E Girard; A Maiga; M Rekik; P Lluel; G Masuyer; M Larregola; C Marquer; J Ciolek; T Magnin; R Wagner; J Molgó; R Thai; C Fruchart-Gaillard; G Mourier; J Chamot-Rooke; A Ménez; S Palea; D Servent; N Gilles
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

Review 8.  Behavioral genetic contributions to the study of addiction-related amphetamine effects.

Authors:  Tamara J Phillips; Helen M Kamens; Jeanna M Wheeler
Journal:  Neurosci Biobehav Rev       Date:  2007-11-29       Impact factor: 8.989

9.  Effects of ρ-Da1a a peptidic α(1) (A) -adrenoceptor antagonist in human isolated prostatic adenoma and anaesthetized rats.

Authors:  S Palea; A Maiga; V Guilloteau; M Rekik; M Guérard; C Rouget; P Rischmann; H Botto; P Camparo; P Lluel; N Gilles
Journal:  Br J Pharmacol       Date:  2013-02       Impact factor: 8.739

Review 10.  The role of the prostatic stroma in chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Marco Dellabella; Giulio Milanese; Sandra Sigala; Gianluca d'Anzeo; Nicola Arrighi; Serena Bodei; Giovanni Muzzonigro
Journal:  Inflamm Res       Date:  2009-12       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.